Activity of nacubactam (RG6080/OP0595) combinations against MBL-producing enterobacteriaceae

Journal of Antimicrobial Chemotherapy

Volumn 74, Issue 4, 2019, Pages 953-960

  Mushtaq, Shazad ^a   Vickers, Anna ^a   Woodford, Neil ^a   Haldimann, Andreas ^b   Livermore, David M ^a,c  

^a PUBLIC HEALTH ENGLAND   (United Kingdom)

^b F HOFFMANN LA ROCHE LTD   (Switzerland)

^c UNIVERSITY OF EAST ANGLIA   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

AVIBACTAM; AZTREONAM; CEFEPIME; MEROPENEM; NACUBACTAM; ANTIINFECTIVE AGENT; AZABICYCLO DERIVATIVE; BETA LACTAM; BETA LACTAMASE INHIBITOR; LACTAM;

AGAR DILUTION; ANTIBACTERIAL ACTIVITY; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ANTIBIOTIC THERAPY; ARTICLE; BACTERIUM ISOLATE; CITROBACTER; COMBINATION DRUG THERAPY; CONTROLLED STUDY; DRUG EFFICACY; DRUG POTENTIATION; ENTEROBACTER; ENTEROBACTERIACEAE; ESCHERICHIA COLI; KLEBSIELLA; METALLO BETA LACTAMASE PRODUCING ENTEROBACTERIACEAE; MINIMUM INHIBITORY CONCENTRATION; MONOTHERAPY; MORGANELLA MORGANII; NONHUMAN; PROTEEAE; PROVIDENCIA; SYNERGISTIC EFFECT; BETA-LACTAM RESISTANCE; DRUG EFFECT; ENTEROBACTERIACEAE INFECTION; HUMAN; ISOLATION AND PURIFICATION; MICROBIAL SENSITIVITY TEST; MICROBIOLOGY; PROSPECTIVE STUDY; UNITED KINGDOM;

ANTI-BACTERIAL AGENTS; AZABICYCLO COMPOUNDS; BETA-LACTAM RESISTANCE; BETA-LACTAMASE INHIBITORS; BETA-LACTAMS; ENTEROBACTERIACEAE; ENTEROBACTERIACEAE INFECTIONS; HUMANS; LACTAMS; MICROBIAL SENSITIVITY TESTS; PROSPECTIVE STUDIES; UNITED KINGDOM;

EID: 85063007272     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dky522     Document Type: Article

References (25)

1. Shlaes DM. New b-lactam-b-lactamase inhibitor combinations in clinical development. Ann NY Acad Sci 2013; 1277: 105-14.
2. Durand-Réville TF, Guler S, Comita-Prevoir J et al. ETX2514 is a broadspectrum b-lactamase inhibitor for the treatment of drug-resistant Gramnegative bacteria including Acinetobacter baumannii. Nat Microbiol 2017; 2: 17104.
3. Morinaka A, Tsutsumi Y, Yamada M et al. OP0595, a new diazabicyclooctane: mode of action as a serine b-lactamase inhibitor, antibiotic and b-lactam 'enhancer'. J Antimicrob Chemother 2015; 70: 2779-86.
4. Hirsch EB, Ledesma KR, Chang KT et al. In vitro activity ofMK-7655, a novel b-lactamase inhibitor, in combination with imipenem against carbapenemresistant Gram-negative bacteria. Antimicrob Agents Chemother 2012; 56: 3753-7.
5. Livermore DM, Mushtaq S, Warner M et al. In vitro activity of cefepime/zidebactam (WCK 5222) against Gram-negative bacteria. J Antimicrob Chemother 2017; 72: 1373-85.
6. Berrazeg M, Diene S, Medjahed L et al. New Delhi metallo-b-lactamase around the world: an eReview using Google Maps. Euro Surveill 2014; 19: pii"20809.
7. Livermore DM, Mushtaq S, Warner M et al. Activities of NXL104 combinations with ceftazidime and aztreonam against carbapenemase-producing Enterobacteriaceae. Antimicrob Agents Chemother 2011; 55: 390-4.
8. Karlowsky JA, Kazmierczak KM, de Jonge BLM et al. In vitro activity of aztreonam-avibactam against Enterobacteriaceae and Pseudomonas aeruginosa isolated by clinical laboratories in 40 countries from 2012 to 2015. Antimicrob Agents Chemother 2017; 61: e00472-17.
9. Livermore DM, Mushtaq S, Warner M et al. Activity of OP0595/b-lactam combinations against Gram-negative bacteria with extended-spectrum, AmpC and carbapenem-hydrolysing b-lactamases. J Antimicrob Chemother 2015; 70: 3032-41.
10. Moya B, Barcelo IM, Bhagwat S et al. WCK 5107 (zidebactam) and WCK 5153 are novel inhibitors of PBP2 showing potent "b-lactam enhancer" activity against Pseudomonas aeruginosa, including multidrug-resistant metallob- lactamase-producing high-risk clones. Antimicrob Agents Chemother 2017; 61: e02529-16.
11. Livermore DM, Warner M, Mushtaq S et al. Interactions of OP0595, a novel triple-action diazabicyclooctane, with b-lactams against OP0595-resistant Enterobacteriaceae mutants. Antimicrob Agents Chemother 2015; 60: 554-60.
12. Doumith M, Mushtaq S, Livermore DM et al. New insights into the regulatory pathways associated with the activation of the stringent response in bacterial resistance to the PBP2-targeted antibiotics, mecillinam and OP0595/RG6080. J Antimicrob Chemother 2016; 71: 2810-14.
13. Ellington MJ, Findlay J, Hopkins KL et al. Multicentre evaluation of a realtime PCR assay to detect genes encoding clinically relevant carbapenemases in cultured bacteria. Int J Antimicrob Agents 2016; 47: 151-4.
14. Swayne RL, Ludlam HA, Shet VG et al. Real-time TaqMan PCR for rapid detection of genes encoding five types of non-metallo- (class A and D) carbapenemases in Enterobacteriaceae. Int J Antimicrob Agents 2011; 38: 35-8.
15. Clinical and Laboratory Standards Institute. Methods for Dilution Antimicrobial Susceptibility Tests for Bacteria That Grow Aerobically - Tenth Edition: M07. CLSI, Wayne, PA, USA, 2015.
16. Kazmierczak KM, Rabine S, Hackel M et al. Multiyear, multinational survey of the incidence and global distribution of metallo-b-lactamase-producing Enterobacteriaceae and Pseudomonas aeruginosa. Antimicrob Agents Chemother 2015; 60: 1067-78.
17. Mushtaq S, Vickers A, Woodford N et al. Potentiation of cefepime by the boronate VNRX-5133 vs. Gram-negative bacteria with known b-lactamases. In: Abstracts of the Twenty-eighth European Conference on Clinical Microbiology and Infectious Diseases, Madrid, Spain, 2018. Abstract P1536.
18. Jain A, Hopkins KL, Turton J et al. NDM carbapenemases in the United Kingdom: an analysis of the first 250 cases. J Antimicrob Chemother 2014; 69: 1777-84.
19. Marquez-Ortiz RA, Haggerty L, Olarte N et al. Genomic epidemiology of NDM-1-encoding plasmids in Latin American clinical isolates reveals insights into the evolution of multidrug resistance. Genome Biol Evol 2017; 9: 1725-41.
20. Saavedra-Rojas SY, Duarte-Valderrama C, González-de-Arias MN et al. Emergence of Providencia rettgeri NDM-1 in two departments of Colombia, 2012-2013. Enferm Infecc Microbiol Clin 2017; 35: 354-8.
21. Sumita Y, Fukasawa M, Okuda T. Comparison of two carbapenems, SM- 7338 and imipenem: affinities for penicillin-binding proteins and morphological changes. J Antibiot (Tokyo) 1990; 43: 314-20.
22. Sumita Y, Fukasawa M. Potent activity of meropenem against Escherichia coli arising from its simultaneous binding to penicillin-binding proteins 2 and 3. J Antimicrob Chemother 1995; 36: 53-64.
23. Georgopapadakou NH, Smith SA, Sykes RB. Mode of action of azthreonam. Antimicrob Agents Chemother 1982; 21: 950-6.
24. Kennedy H, Wilson S, Marwick C et al. Reduction in broad-spectrum Gram-negative agents by diverse prescribing of aztreonam within NHS Tayside. J Antimicrob Chemother 2015; 70: 2421-3.
25. Pultz NJ, Donskey CJ. Effect of antibiotic treatment on growth of and toxin production by Clostridium difficile in the cecal contents of mice. Antimicrob Agents Chemother 2005; 49: 3529-32.